Acute Myeloid Leukemia - Allogeneic Transplant Study
CALGB 100103: A Phase II Study of Allogeneic Transplant for Older Patients with AML in First Morphologic complete remission using a Non-Myeloablative preparation regimen
Protocol ID
07-121
Protocol Description
The goal of this study is to replace the defective cells responsible for acute myeloid leukemia with normal cells from a non-affected donor. This experimental treatment is a new approach that attempts to stimulate a patient's own immune system to fight his/her disease.
Eligibility Criteria
Patients with acute myeloid leukemia and non-affected donors
Primary Investigator(s)
- Ruthee-Lu Bayer, MD
Contact Information
Last Update
March 26, 2010How did I get to this page?
Persistent Navigation
- Home
- About Us
- Centers of Excellence
- Our Laboratories
- Research Topics
-
Clinical Trials
- Addiction
- Aging
- Allergies
- Arthritis
- Autoimmune Disease
- Blood Disorders
- Cancer
- Children's Health
- Circulation
- Diabetes
- Ear & Hearing
- Eyes
- Gastrointestinal/Hepatitis
- Genetics
- Heart
- HIV
- Infectious Diseases
- Joints
- Kidney
- Lung
- Lupus
- Men's Health
- Mental Health
- Neurosciences
- Radiation Medicine
- Recruitment Registry
- Skin
- Sleep Disorders
- Smoking
- Urinary Tract
- Weight Control
- Women's Health
- Academics
- Resources for Investigators
- Upcoming Events